<DOC>
	<DOCNO>NCT01518998</DOCNO>
	<brief_summary>The purpose study evaluate antihypertensive efficacy safety Fimasartan</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled , 3x3 Factorial Design , Phase II Study Evaluate Antihypertensive Efficacy Safety Combination Fimasartan Amlodipine Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Subjects agree participate study submit write informed consent 2 . Subjects age 20 75 year 3 . Essential hypertension subject measure 90mmHg , less 114mmHg sit diastolic blood pressure ( SiDBP ) baseline ( day 0 ) . 4 . Subjects consider understand study , cooperative , able followedup whole study period . 1 . Severe hypertension patient ; 115mmHg SiDBP and/or 185 mmHg Sitting systolic blood pressure ( SiSBP ) 2 . Patients secondary hypertension 3 . Patients significant investigation abnormal renal function ( Creatinine 1.5 time upper limit normal ) , abnormal liver function ( AST , ALT 2 time upper normal ) , moderate fatty lever need medication 4 . Patients significant investigation Hypokalemia ( Less 3.5mmol/L ) , Hyperkalemia ( exceed 5.5mmol/L ) 5 . Patients sodium ion body fluid deplete able correct 6 . Patients hypotension sign symptom 7 . Patients surgical medical disease able affect absorption , distribution , metabolism , excretion 8 . Patients severe insulin dependent uncontrolled diabetes mellitus ( HbA1c &gt; 9 % , regimen change oral hypoglycemic agent , use insulin ) 9 . Patients severe heart disease , ischemic heart disease within 6months , peripheral vascular disease , Percutaneous Transluminal Coronary Angiography ( PTCA ) , Coronary Artery Bypass Graft ( CABG ) 10 . Patients significant ventricular tachycardia , atrial fibrillation , atrial flutter significant arrhythmia 11 . Patients hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically significant aortic valve mitral valve disease 12 . Patients severe cerebrovascular disease 13 . Patients waste disease , autoimmune disease , connective tissue disease present and/or previous . 14 . Patients know severe malignancy retinopathy 15 . Patients hepatitis B C HIV positive reaction 16 . Patients story evidence alcohol drug abuse within 2years 17 . Patients measure mean difference mean blood pressure arm SiDBP 10mmHg SiSBP 20mmHg screen baseline visit 18 . Patients history allergic reaction angiotensin II antagonist 19 . Patients chronic inflammation disease need chronic inflammation therapy 20 . Patients medical history malignant tumor within 5years , except local basal cell carcinoma skin 21 . Childbearing breastfeed woman 22 . Female plan become pregnancy possibility pregnancy n't prevent conception acknowledge method 23 . Patients take medicine within 12 week screen visit go progress clinical trial 24 . Subject judge unsuitable participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Fimasartan</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>antihypertension</keyword>
</DOC>